The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

which may be different from the current recommendations for people living with diabetes and obesity. “These data suggest the potential of semaglutide and similar drugs to fill an unmet need for ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...